Analyst Price Targets — CELC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 17, 2026 10:56 am | Brad Canino | Guggenheim | $175.00 | $92.00 | StreetInsider | Celcuity Inc (CELC) PT Raised to $175 at Guggenheim |
| August 14, 2026 11:04 am | Gil Blum | Needham | $140.00 | $86.60 | StreetInsider | Celcuity Inc (CELC) PT Lowered to $140 at Needham |
| July 15, 2026 1:23 pm | — | Craig-Hallum | $178.00 | $90.09 | TheFly | Celcuity price target raised to $178 from $171 at Craig-Hallum |
| July 15, 2026 9:59 am | — | H.C. Wainwright | $155.00 | $111.05 | TheFly | Celcuity price target raised to $155 from $145 at H.C. Wainwright |
| June 3, 2026 12:48 pm | — | Craig-Hallum | $171.00 | $89.12 | TheFly | Celcuity price target lowered to $171 from $189 at Craig-Hallum |
| June 3, 2026 10:07 am | — | H.C. Wainwright | $145.00 | $91.42 | TheFly | Celcuity price target lowered to $145 from $185 at H.C. Wainwright |
| June 3, 2026 9:28 am | Eva Fortea Verdejo | Wells Fargo | $166.00 | $91.42 | StreetInsider | Celcuity Inc (CELC) PT Lowered to $166 at Wells Fargo |
| June 2, 2026 1:21 pm | Andrew Berens | Leerink Partners | $155.00 | $93.37 | StreetInsider | Celcuity Inc (CELC) PT Lowered to $155 at Leerink, 'we expect CELC shares to be under pressure given the lofty expectations' |
| May 28, 2026 9:56 am | — | Macquarie | $160.00 | $133.97 | StreetInsider | Celcuity (CELC) Reiterated at Market Outperform by Citizens Ahead of ASCO Presentation |
| May 18, 2026 10:04 am | Swayampakula Ramakanth | H.C. Wainwright | $185.00 | $137.68 | TheFly | Celcuity price target raised to $185 from $165 at H.C. Wainwright |
Latest News for CELC
MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:
MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive…
Brandywine Managers LLC acquired a new stake in shares of Celcuity, Inc. (NASDAQ: CELC) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 6,621 shares of the company's stock, valued at approximately $693,000. Several other hedge funds have also
Celcuity Inc. remains a Buy as the REVTORPYK/gedatolisib FDA approval and rapid NCCN Category 1 inclusion de-risk clinical and commercial adoption. CELC's financials reflect a front-loaded commercial investment, with SG&A surging for launch, but a strengthened $754M cash position provides funding visibility into 2029. VIKTORIA-1 data show REVTORPYK delivers a step-change in efficacy and tolerability, supporting…
Celcuity Inc (NASDAQ:CELC) reported a narrower-than-expected loss for the second quarter on Thursday.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CELC.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.